

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Overview of Results

Table A Olympic and Non-Olympic: Adverse Analytical Findings Rate

Differentiation between Olympic and Non-Olympic Sports	A Samples Analyzed	A Samples Adverse Analytical Findings*	% Adverse
Olympic Sports	156,866	2,915	1.86%
Non-Olympic Sports	41,277	972	2.35%
TOTAL	198,143	3,887	1.96%

* **NOTE: The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV).** "Adverse Analytical Finding" is defined in the World Anti-Doping Code as "a report from a laboratory or approved Testing entity that identifies in a Specimen the presence of a Prohibited Substance or its Metabolites or Markers (including elevated quantities of endogenous substances) or evidence of the Use of a Prohibited Method." These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings may correspond to multiple measurements performed on the same athlete, such as in cases of longitudinal studies on testosterone.

Adverse Analytical Findings

Comparison of years 2003 to 2006

Table A1 Olympic and Non-Olympic: Adverse Analytical Findings

Differentiation between Olympic and Non-Olympic Sports	2003 A Samples Analyzed	2004 A Samples Analyzed	2005 A Samples Analyzed	2006 A Samples Analyzed	% difference 2006 vs 2005
Olympic Sports	113,559	128,591	139,836	156,866	12.2%
Non-Olympic Sports	37,651	40,596	43,501	41,277	-5.1%
TOTAL	151,210	169,187	183,337	198,143	8.1%

Differentiation between Olympic and Non-Olympic Sports	2003 A Samples Adverse Analytical Findings*	2004 A Samples Adverse Analytical Findings*	2005 A Samples Adverse Analytical Findings*	2006 A Samples Adverse Analytical Findings*	% difference 2006 vs 2005
Olympic Sports	1,707	2,145	2,958	2,915	-1.5%
Non-Olympic Sports	740	764	951	972	2.2%
TOTAL	2,447	2,909	3,909	3,887	-0.6%

Differentiation between Olympic and Non-Olympic Sports	2003 % Adverse	2004 % Adverse	2005 % Adverse	2006 % Adverse	% difference 2006 vs 2005
Olympic Sports	1.50	1.67	2.12	1.86	-12.2%
Non-Olympic Sports	1.97	1.88	2.19	2.35	7.3%
Overall	1.62	1.72	2.13	1.96	-7.9%

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table B Total Adverse Analytical Findings per Laboratory
(Olympic and Non-Olympic Sports)

Laboratory		N Total	N Adverse Analytical Findings*	% Adverse
1	Sydney , Australia	7,574	129	1.70
2	Seibersdorf , Austria	5,931	119	2.01
3	Ghent , Belgium	5,682	268	4.72
4	Rio de Janeiro , Brazil	4,208	20	0.48
5	Montreal , Canada	14,706	294	2.00
6	Beijing , China	8,572	66	0.77
7	Bogota , Colombia	2,717	56	2.06
8	Havana , Cuba	1,933	24	1.24
9	Prague , Czech Republic	1,659	122	7.35
10	Helsinki , Finland	1,858	57	3.07
11	Paris , France	8,394	454	5.41
12	Cologne , Germany	11,006	279	2.53
13	Kreischa , Germany	5,870	169	2.88
14	Cambridge , UK	1,508	15	0.99
15	London , UK	8,594	98	1.14
16	Athens , Greece	4,699	69	1.47
17	Rome , Italy	8,319	222	2.67
18	Tokyo , Japan	4,004	23	0.57
19	Seoul , Korea	3,581	21	0.59
20	Penang , Malaysia	2,498	49	1.96
21	Oslo , Norway	4,683	102	2.18
22	Warsaw , Poland	2,123	65	3.06
23	Lisbon , Portugal	3,494	116	3.32
24	Bloemfontein , South Africa	3,158	50	1.58
25	Moscow , Russia	5,525	58	1.05
26	Barcelona , Spain	3,684	83	2.25
27	Madrid , Spain	6,652	124	1.86
28	Stockholm , Sweden	4,028	129	3.20
29	Lausanne , Switzerland	3,865	120	3.10
30	Bangkok , Thailand	1,658	21	1.27
31	Tunis , Tunisia	1,499	32	2.13
32	Ankara , Turkey	3,760	28	0.74
33	Los Angeles , USA	39,097	386	0.99
34	Salt Lake City , USA	1,604	19	1.18
TOTAL		198,143	3,887	1.96%

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table B1 Olympic Sport Adverse Analytical Findings per Laboratory

Laboratory		N Total	N Adverse Analytical Findings*	% Adverse
1	Sydney , Australia	4,615	89	1.93
2	Seibersdorf , Austria	5,420	92	1.70
3	Ghent , Belgium	4,734	184	3.89
4	Rio de Janeiro , Brazil	4,158	10	0.24
5	Montreal , Canada	14,040	263	1.87
6	Beijing , China	8,079	63	0.78
7	Bogota , Colombia	2,455	53	2.16
8	Havana , Cuba	1,803	21	1.16
9	Prague , Czech Republic	1,371	81	5.91
10	Helsinki , Finland	1,392	40	2.87
11	Paris , France	6,575	339	5.16
12	Cologne , Germany	9,640	178	1.85
13	Kreischa , Germany	5,300	144	2.72
14	Cambridge , UK	1,102	6	0.54
15	London , UK	6,392	60	0.94
16	Athens , Greece	4,169	62	1.49
17	Rome , Italy	7,313	194	2.65
18	Tokyo , Japan	3,545	17	0.48
19	Seoul , Korea	2,742	9	0.33
20	Penang , Malaysia	1,825	17	0.93
21	Oslo , Norway	3,781	77	2.04
22	Warsaw , Poland	2,026	51	2.52
23	Lisbon , Portugal	2,764	72	2.60
24	Bloemfontein , South Africa	2,129	35	1.64
25	Moscow , Russia	5,289	53	1.00
26	Barcelona , Spain	3,336	62	1.86
27	Madrid , Spain	5,688	92	1.62
28	Stockholm , Sweden	3,115	99	3.18
29	Lausanne , Switzerland	3,429	102	2.97
30	Bangkok , Thailand	835	17	2.04
31	Tunis , Tunisia	1,285	18	1.40
32	Ankara , Turkey	3,243	26	0.80
33	Los Angeles , USA	23,276	289	1.24
34	Salt Lake City , USA	-	-	-
TOTAL		156,866	2,915	1.86%

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table B2 Non-Olympic Sport Adverse Analytical Findings per Laboratory

Laboratory		N Total	N Adverse Analytical Findings*	% Adverse
1	Sydney , Australia	2,959	40	1.35
2	Seibersdorf , Austria	511	27	5.28
3	Ghent , Belgium	948	84	8.86
4	Rio de Janeiro , Brazil	50	10	20.00
5	Montreal , Canada	666	31	4.65
6	Beijing , China	493	3	0.61
7	Bogota , Colombia	262	3	1.15
8	Havana , Cuba	130	3	2.31
9	Prague , Czech Republic	288	41	14.24
10	Helsinki , Finland	466	17	3.65
11	Paris , France	1,819	115	6.32
12	Cologne , Germany	1,366	101	7.39
13	Kreischa , Germany	570	25	4.39
14	Cambridge , UK	406	9	2.22
15	London , UK	2,202	38	1.73
16	Athens , Greece	530	7	1.32
17	Rome , Italy	1,006	28	2.78
18	Tokyo , Japan	459	6	1.31
19	Seoul , Korea	839	12	1.43
20	Penang , Malaysia	673	32	4.75
21	Oslo , Norway	902	25	2.77
22	Warsaw , Poland	97	14	14.43
23	Lisbon , Portugal	730	44	6.03
24	Bloemfontein , South Africa	1,029	15	1.46
25	Moscow , Russia	236	5	2.12
26	Barcelona , Spain	348	21	6.03
27	Madrid , Spain	964	32	3.32
28	Stockholm , Sweden	913	30	3.29
29	Lausanne , Switzerland	436	18	4.13
30	Bangkok , Thailand	823	4	0.49
31	Tunis , Tunisia	214	14	6.54
32	Ankara , Turkey	517	2	0.39
33	Los Angeles , USA	15,821	97	0.61
34	Salt Lake City , USA	1,604	19	1.18
TOTAL		41,277	972	2.35%

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table C

Olympic Sport Sample Analysis

Sport	Discipline	Total per Discipline	Total per Sport	A Sample Adverse Analytical Findings*	% Adverse
Aquatics	Aquatics	1,799	11,582	137	1.18%
	Diving	308			
	Swimming	8,035			
	Synchronised Swimming	475			
	Water Polo	965			
Archery	Archery	-	845	11	1.30%
Athletics	Athletics	-	19,781	315	1.59%
Badminton	Badminton	-	1,066	10	0.94%
Baseball	Baseball	-	15,977	370	2.32%
Basketball	Basketball	-	7,473	136	1.82%
Biathlon	Biathlon	-	1,094	21	1.92%
Bobsleigh	Bobsleigh	847	908	13	1.43%
	Tobogganing	14			
	Skeleton	47			
Boxing	Boxing	-	2,553	61	2.39%
Canoe / Kayak	Canoe / Kayak	-	2,918	34	1.17%
Curling	Curling	-	350	2	0.57%
Cycling	Cycling	14,021	14,229	594	4.17%
	Mountain Bike	208			
Equestrian	Equestrian	-	579	8	1.38%
Fencing	Fencing	-	1,837	11	0.60%
Football	Football	-	25,727	281	1.09%
Gymnastics	Gymnastics	1,889	2,102	21	1.00%
	Artistic Gymnastics	99			
	Rhythmic Gymnastics	54			
	Trampoline	60			
Handball	Handball	-	2,568	51	1.99%
Hockey	Hockey	-	1,744	32	1.83%
Ice Hockey	Ice Hockey	-	5,011	94	1.88%
Judo	Judo	-	3,121	45	1.44%
Luge	Luge	-	208	3	1.44%
Modern Pentathlon	Modern Pentathlon	-	480	10	2.08%
Rowing	Rowing	-	3,221	53	1.65%
Sailing	Sailing	-	1,000	17	1.70%
Shooting	Shooting	-	2,406	13	0.54%
Skating	Skating	1,496	3,078	41	1.33%
	Speed Skating	1,159			
	Figure Skating	423			
Skiing	Skiing	2,181	3,901	76	1.95%
	Alpine Skiing	365			
	Cross Country Ski	161			
	Ski Jumping	645			
	Snowboard	140			
	Combined Skiing	102			
	Freestyle Skiing	307			
Softball	Softball	-	491	7	1.43%
Table Tennis	Table Tennis	-	827	10	1.21%
Taekwondo	Taekwondo	-	1,328	21	1.58%
Tennis	Tennis	-	2,748	44	1.60%
Triathlon	Triathlon	-	2,366	67	2.83%
Volleyball	Volleyball	3,199	3,340	48	1.44%
	Beach Volleyball	141			
Weightlifting	Weightlifting	-	6,543	187	2.86%
Wrestling	Wrestling	-	3,055	58	1.90%
Baseball / Softball ¹		-	104	6	5.77%
Hockey / Skating ¹		-	16	0	0.00%
Ice Sport ¹		-	289	7	2.42%
Total			156,866	2,915	1.86%

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

¹ "Baseball/Softball," "Hockey/Skating," "Ice Sport" were designated on Doping Control Forms and unable to assign by single sport or federation.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table D1 Sample Analysis in Selected** IOC Recognized Sports

Sport	Discipline	Total per Discipline	Total per Sport	Adverse Analytical Findings*	% adverse (discipline)	% adverse (Sport)
Rollersports	Roller Hockey	133	784	22	-	2.81%
	Roller Skating	515				
	Roller Sports	136				
Golf	Golf	-	412	11	-	2.67%
Karate	Karate	-	727	13	-	1.79%
Rugby	Rugby	3,122	4,782	106	3.40%	2.63%
	Rugby Union	1,660		20	1.20%	
Squash	Squash	-	419	5	-	1.19%
TOTAL			7,124	177	-	2.48%

** as requested by the International Olympic Committee.

Table D2 Sample Analysis in Other IOC Recognized Sports

Sport	Total per Sport	Adverse Analytical Findings*	% Adverse
Air Sports	97	9	9.28%
Bandy	94	3	3.19%
Billiard Sports	326	24	7.36%
Boules	356	6	1.69%
Bowling	318	10	3.14%
Bridge	39	3	7.69%
Chess	75	1	1.33%
Dance Sport	194	4	2.06%
Korfball	54	0	0.00%
Life Saving	264	4	1.52%
Motorcycle Racing	368	10	2.72%
Mountaineering and Climbing	261	3	1.15%
Netball	265	2	0.75%
Orienteering	463	16	3.46%
Pelote Basque	86	1	1.16%
Polo	10	0	0.00%
Powerboating	249	5	2.01%
Racquetball	63	2	3.17%
Sumo	79	2	2.53%
Surfing	91	3	3.30%
Tug of War	106	1	0.94%
Underwater Sports	387	4	1.03%
Water Skiing	207	4	1.93%
Wushu	141	0	0.00%
TOTAL	4,593	117	2.55%

Table E Sample Analysis in Paralympic Sports

Sport	Total per Sport	Adverse Analytical Findings*	% Adverse
Paralympic Sports	1,881	41	2.18%

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table F Number of Substances Identified in Each Drug Class

Substance Group	Number*	% of all adverse analytical findings
S1. Anabolic Agents	1,966	45.4%
S3. Beta-2 Agonists	631	14.6%
S8. Cannabinoids	553	12.8%
S6. Stimulants	490	11.3%
S5. Diuretics and Other Masking Agents	290	6.7%
S9. Glucocorticosteroids	282	6.5%
S2. Hormones and Related Substances	42	1.0%
P2. Beta-Blockers	28	0.6%
S4. Agents with Anti-Estrogenic Activity	30	0.7%
S7. Narcotics	16	0.4%
M2. Chemical and Physical Manipulation	4	0.1%
TOTAL	4,332	

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table G Substances Identified in Each Drug Class

S1.1.a. Anabolic Agents - Exogenous AAS	Occurrences	% within drug class
Nandrolone	237	12.1%
Stanozolol	222	11.3%
Methandienone	126	6.4%
Boldenone	37	1.9%
Methyltestosterone	33	1.7%
Metenolone	30	1.5%
Mesterolone	22	1.1%
Drostanolone	17	0.9%
Trenbolone	9	0.5%
Oxandrolone	7	0.4%
Oxymetholone	6	0.3%
Clostebol	4	0.2%
Dehydrochlormethyltestosterone	2	0.1%
Mestanolone	2	0.1%
Desoxymethyltestosterone	2	0.1%
Danazol	1	0.1%
1-testosterone	1	0.1%
1-androstendione	1	0.1%
Oxymesterone	1	0.1%
Prostanazol	1	0.1%
subtotal*	761	

S1.1.b. Anabolic Agents - Endogenous AAS¹	Occurrences	% within drug class
Testosterone	1,124	57.2%
Testosterone precursor(s)	13	0.7%
Prasterone (DHEA)	11	0.6%
Etiocholanolone	3	0.2%
Androsterone	1	0.1%
subtotal*	1,152	

S.1.2 Other Anabolic Agents	Occurrences	% within drug class
Clenbuterol	53	2.7%
subtotal*	53	

S.1. All Anabolic Agents	Occurrences
TOTAL*	1,966

¹ Reporting of an Endogenous AAS may be due to detection of a concentration outside normal reference ranges and/or establishment of an exogenous source by GC/C/IRMS.

S2. Hormones and Related Substances	Occurrences	% within drug class
Gonadotrophins (hCG)	22	52.4%
Erythropoetin (EPO)	17	40.5%
Gonadotrophins (LH)	2	4.8%
Erythropoetin (Darbepoetin)	1	2.4%
TOTAL*	42	

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table G Substances Identified in Each Drug Class
(cont'd)

S3. Beta-2 Agonists¹	Occurrences	% within drug class
Salbutamol	391	62.0%
Terbutaline	175	27.7%
Formoterol	42	6.7%
Salmeterol	16	2.5%
Fenoterol	5	0.8%
Reproterol	2	0.3%
TOTAL **	631	

¹ Clenbuterol removed and placed into "S1.2 Other Anabolic Agents" as per Prohibited List

S4. Agents with anti-estrogenic activity	Occurrences	% within drug class
Tamoxifen	11	36.7%
Formestane	5	16.7%
Clomiphene	4	13.3%
Anastrozole	4	13.3%
6-oxo-androstenedione	1	3.3%
Androst-1,4,6-triene-3,17-dione (ATD)	1	3.3%
Cylcofenil	1	3.3%
Exemestane	1	3.3%
Letrozole	1	3.3%
Aminoglutethimide	1	3.3%
TOTAL *	30	

S5. Diuretics and other masking agents	Occurrences	% within drug class
Furosemide	90	31.0%
Hydrochlorothiazide	88	30.3%
Finasteride	44	15.2%
Epitestosterone	15	5.2%
Amiloride	10	3.4%
Canrenone	8	2.8%
Chlortalidone	8	2.8%
Triamterene	7	2.4%
Indapamide	5	1.7%
Bumetanide	5	1.7%
Bendroflumethazide	2	0.7%
Acetazolamide	2	0.7%
Probenecid	2	0.7%
Chlorothiazide	1	0.3%
Althiazide	1	0.3%
Diclofenamide	1	0.3%
Epitizide	1	0.3%
TOTAL *	290	

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table G
(cont'd)

Substances Identified in Each Drug Class

M2. Chemical and Physical Manipulation	Occurrences	% within drug class
Physical Manipulation	4	100.0%
TOTAL*	4	

S6. Stimulants	Occurrences	% within drug class
Amphetamine	199	40.6%
Cocaine	85	17.3%
Ephedrine	66	13.5%
Methylphenidate	32	6.5%
Cathine	22	4.5%
Phentermine	13	2.7%
Methylenedioxymethamphetamine	9	1.8%
Modafinil	9	1.8%
Methamphetamine	8	1.6%
Heptaminol	8	1.6%
Securinine	7	1.4%
4-phenylpiracetam (carphedon)	5	1.0%
Norfenfluramine	5	1.0%
Mephentermine	4	0.8%
Methylenedioxyamphetamine	3	0.6%
Nikethamide	3	0.6%
Sibutramine	3	0.6%
Strychnine	2	0.4%
Phenmetrazine	1	0.2%
Etilefrine	1	0.2%
Pemoline	1	0.2%
Isometheptene	1	0.2%
Methoxyphenamine	1	0.2%
Pholedrine	1	0.2%
Propylhexedrine	1	0.2%
TOTAL*	490	

S7. Narcotics	Occurrences	% within drug class
Morphine	11	68.8%
Methadone	3	18.8%
Hydromorphone	1	6.3%
Pethidine	1	6.3%
TOTAL*	16	

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories

Table G Substances Identified in Each Drug Class
(cont'd)

S8. Cannabinoids	Occurrences	% within drug class
Cannabinoids	553	100.0%
TOTAL*	553	

S9. Glucocorticosteroids	Occurrences	% within drug class
Budesonide	142	50.4%
Betamethasone	45	16.0%
Prednisolone	30	10.6%
Prednisone	20	7.1%
Triamcinolone Acetonide	18	6.4%
Prednisolone + Prednisone	9	3.2%
Methylprednisolone	9	3.2%
Dexamethasone	9	3.2%
TOTAL*	282	

P2. Beta Blockers	Occurrences	% within drug class
Atenolol	9	32.1%
Metoprolol	6	21.4%
Propranolol	6	21.4%
Carvedilol	3	10.7%
Bisoprolol	2	7.1%
Timolol	2	7.1%
TOTAL*	28	

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.

2006 Adverse Analytical Findings Reported by Accredited Laboratories
Table H Total Laboratory Adverse Analytical Findings* vs Drug Class

Laboratory	S1. Anabolic Agents	S2. Hormones and Related Substances	S3. Beta-2 Agonists	S4. Agents with Anti- Estrogenic Activity	S5. Diuretics and Other Masking Agents	S6. Stimulants	S7. Narcotics	S8. Cannabinoids	S9. Glucocortico- steroids	P2. Beta- Blockers	Other	Total per Lab	% of total adverse analytical findings
Sydney, Australia	101	-	2	-	2	8	-	20	-	-	-	133	3.1%
Seibersdorf, Austria	78	1	19	-	8	5	-	17	3	-	-	131	3.0%
Ghent, Belgium	159	7	33	2	16	39	6	58	13	-	-	333	7.7%
Rio de Janeiro, Brazil	6	-	2	-	5	8	-	3	-	-	-	24	0.6%
Montreal, Canada	45	1	36	2	21	104	1	88	10	-	-	308	7.1%
Beijing, China	40	-	4	-	16	8	1	-	-	1	-	70	1.6%
Bogota, Colombia	38	-	5	-	10	4	-	2	1	-	-	60	1.4%
Havana, Cuba	22	-	-	-	1	-	-	-	1	-	-	24	0.6%
Prague, Czech Republic	142	1	12	4	3	6	-	7	-	1	-	176	4.1%
Helsinki, Finland	32	-	19	-	3	1	-	1	3	-	-	59	1.4%
Paris, France	200	3	84	1	27	23	-	94	86	1	-	519	12.0%
Cologne, Germany	169	1	59	2	29	23	1	16	13	1	4	318	7.3%
Kreischa, Germany	76	2	69	-	5	2	2	3	21	1	-	181	4.2%
Cambridge, UK	4	1	5	-	2	1	-	2	-	-	-	15	0.3%
London, UK	53	2	5	-	2	22	-	16	-	-	-	100	2.3%
Athens, Greece	27	-	7	-	4	5	-	11	17	1	-	72	1.7%
Rome, Italy	87	4	60	1	23	21	-	20	31	3	-	250	5.8%
Tokyo, Japan	9	-	6	-	3	4	-	-	1	-	-	23	0.5%
Seoul, Korea	17	-	3	5	2	4	-	-	-	-	-	31	0.7%
Penang, Malaysia	39	-	2	-	1	-	-	3	1	3	-	49	1.1%
Oslo, Norway	43	-	35	-	4	3	-	4	14	-	-	103	2.4%
Warsaw, Poland	67	-	-	2	3	6	-	2	-	-	-	80	1.8%
Lisbon, Portugal	50	4	9	-	19	11	-	17	8	9	-	127	2.9%
Bloemfontein, S Africa	25	2	3	1	4	2	-	15	2	-	-	54	1.2%
Moscow, Russia	39	-	3	-	9	4	2	2	1	2	-	62	1.4%
Barcelona, Spain	61	6	14	4	10	2	-	11	2	1	-	111	2.6%
Madrid, Spain	3	4	64	-	11	7	1	20	12	2	-	124	2.9%
Stockholm, Sweden	77	-	46	1	5	5	-	1	25	-	-	160	3.7%
Lausanne, Switzerland	68	1	20	3	7	3	1	8	8	2	-	121	2.8%
Bangkok, Thailand	13	-	-	-	4	5	-	-	3	-	-	25	0.6%
Tunis, Tunisia	15	-	3	-	6	1	-	12	1	-	-	38	0.9%
Ankara, Turkey	13	-	-	-	7	5	-	4	-	-	-	29	0.7%
Los Angeles, USA	148	2	2	2	13	134	1	96	5	-	-	403	9.3%
Salt Lake City, USA	-	-	-	-	5	14	-	-	-	-	-	19	0.4%
TOTAL PER DRUG CLASS	1,966	42	631	30	290	490	16	553	282	28	4	4,332	
% of Drug Class	45.4%	1.0%	14.6%	0.7%	6.7%	11.3%	0.4%	12.8%	6.5%	0.6%	0.1%		

* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some adverse analytical findings correspond to multiple measurements performed on the same athlete, such as in the case of longitudinal studies on testosterone.